Loss of bone with advancing age is accompanied by oxidative stress (OS) and reduced bone formation associated with diminished osteoblast number and increased osteoblast apoptosis. However, the molecular mechanisms underlying these changes are poorly understood;and it is unclear how intermittent administration of parathyroid hormone (PTH) stimulates bone formation in the elderly in the face of these pathologic changes. It is hypothesized that lipid oxidation, the same mechanism implicated in the pathogenesis of atherosclerosis, also adversely affects bone metabolism. Specifically, the lipoxygenase Aloxl 5 causes OS in the skeleton by oxidizing polyunsaturated fatty acids to generate the pro-oxidant 4- hydroxynonenal (4-HNE), leading to activation of p66 [Shc] - a redo signaling protein that further amplifies OS. The combined effects of OS and lipid oxidation reduce the differentiation and survival of osteoblasts via PPARy-mediated actions that decrease Wnt signaling. It is also proposed that PTH attenuates OS by decreasing p66[Shc] activation, suppressing AloxIS expression, and increasing the synthesis of the 4-HNE scavenging enzyme aldehyde dehydrogenase 3a1 (Alclh3a1). To advance these interrelated hypotheses, the contribution of Aloxl5-mediated generation of 4-HNE to the OS and bone loss caused by aging, ovariectomy, or hyperiipidemia in the ApoE knockout (ApoE KO) mouse model of atherosclerosis, will be determined by conditional deletion of Aloxl 5 or conditional overexpression of Aldh3a1. The contribution of OS and PPARy activation to the decline in Wnt signaling, osteoblast number and bone mass in these models will be investigated by deletion of p66[hsc], and by conditional deletion of PPARy from osteoblast progenitors. Finally, the contribution of the anfioxidant property of intermittent PTH to its anabolic efficacy will be studied in aged mice or ApoE KO mice in which OS has been reduced by deletion of p66 [Shc]'We will also investigate the signaling pathways and anti-oxidant enzymes underlying the ability of PTH to attenuate OS. Efforts to determine the contribution of lipid oxidation to the loss of bone mass in aged and hyperlipidemic atherosclerotic mice could establish common mechanisms for osteoporosis and atherosclerosis, and eventually lead to new therapies that simultaneously combat osteoporosis and other age-related diseases. Elucidation of the relevance of PTH-mediated suppression of OS and lipid oxidation to its anabolic efficacy may reveal new approaches for the treatment of osteoporosis.

Public Health Relevance

Osteoporosis is the most common metabolic disorder of old age. The resulting fractures incur high social and monetary costs, and lead to increased mortality. The studies proposed in this project will investigate the contribution of lipid oxidation and oxidative stress (the same mechanisms implicated in atherosclerosis) to the development of osteoporosis;and the possibility that a novel anti-oxidant property of parathyroid hormone, the only FDA-approved anabolic therapy for osteoporosis, contributes to its efficacy in the elderly.

Agency
National Institute of Health (NIH)
Type
Research Program Projects (P01)
Project #
5P01AG013918-18
Application #
8663773
Study Section
Special Emphasis Panel (ZAG1)
Project Start
Project End
Budget Start
Budget End
Support Year
18
Fiscal Year
2014
Total Cost
Indirect Cost
Name
University of Arkansas for Medical Sciences
Department
Type
DUNS #
City
Little Rock
State
AR
Country
United States
Zip Code
72205
Piemontese, Marilina; Onal, Melda; Xiong, Jinhu et al. (2016) Low bone mass and changes in the osteocyte network in mice lacking autophagy in the osteoblast lineage. Sci Rep 6:24262
Zhu, Meiling; Sun, Ben-Hua; Saar, Katarzyna et al. (2016) Deletion of Rac in Mature Osteoclasts Causes Osteopetrosis, an Age-Dependent Change in Osteoclast Number, and a Reduced Number of Osteoblasts In Vivo. J Bone Miner Res 31:864-73
Jilka, Robert L (2016) The Road to Reproducibility in Animal Research. J Bone Miner Res 31:1317-9
Fujiwara, Yuko; Piemontese, Marilina; Liu, Yu et al. (2016) RANKL (Receptor Activator of NFκB Ligand) Produced by Osteocytes Is Required for the Increase in B Cells and Bone Loss Caused by Estrogen Deficiency in Mice. J Biol Chem 291:24838-24850
Fujiwara, T; Zhou, J; Ye, S et al. (2016) RNA-binding protein Musashi2 induced by RANKL is critical for osteoclast survival. Cell Death Dis 7:e2300
Ye, Shiqiao; Fujiwara, Toshifumi; Zhou, Jian et al. (2016) LIS1 Regulates Osteoclastogenesis through Modulation of M-SCF and RANKL Signaling Pathways and CDC42. Int J Biol Sci 12:1488-1499
Fujiwara, Toshifumi; Ye, Shiqiao; Castro-Gomes, Thiago et al. (2016) PLEKHM1/DEF8/RAB7 complex regulates lysosome positioning and bone homeostasis. JCI Insight 1:e86330
Kim, Ha-Neui; Han, Li; Iyer, Srividhya et al. (2015) Sirtuin1 Suppresses Osteoclastogenesis by Deacetylating FoxOs. Mol Endocrinol 29:1498-509
Piemontese, Marilina; Onal, Melda; Xiong, Jinhu et al. (2015) Suppression of autophagy in osteocytes does not modify the adverse effects of glucocorticoids on cortical bone. Bone 75:18-26
Ucer, Serra; Iyer, Srividhya; Bartell, Shoshana M et al. (2015) The Effects of Androgens on Murine Cortical Bone Do Not Require AR or ERα Signaling in Osteoblasts and Osteoclasts. J Bone Miner Res 30:1138-49

Showing the most recent 10 out of 151 publications